Engineering the Next Generation of Therapeutic Proteins

Advances in protein language models, generative design, structural biology, high-throughput experimentation and protein analytics are rapidly expanding the possibilities of therapeutic protein engineering. Yet as designed proteins move from computational promise toward clinical reality, the challenge is no longer simply generating protein candidates, but understanding which molecules possess the stability, functionality, developability and manufacturability required for successful therapeutic translation, at scale. 

The inaugural Protein Design & Engineering in Biopharma Summit arrived to bring together 80+ carefully selected leaders across protein engineering, structural biology, computational biology, biophysics, developability and biologics R&D. Unlike broader AI, biologics or drug discovery meetings, this highly technical and industry-focused forum intended to provide a rare opportunity to examine the entire Design-Build-Test-Learn cycle, from rational and de novo design through experimental validation, protein characterization, optimization and translational development. 

Through practical case studies and peer-led discussion, attendees could have benchmarked integrated computational and wet-lab workflows, explored strategies to improve design predictability, and accelerated iteration cycles across antibodies, enzymes, mini-proteins, vaccines and next-generation biologics. Attendees could have joined the scientists defining the future of therapeutic protein engineering and left with actionable insights, meaningful collaborations and proven approaches to translate better protein designs into successful therapeutics.